How much does lurbinectedin extend survival in late-stage cancer?
The provided information does not include efficacy results (such as median overall survival or survival-rate improvements) for lurbinectedin in late-stage cancer. Without those trial outcomes, it is not possible to state how much lurbinectedin extends life.
Which late-stage cancers were studied, and what survival numbers were reported?
Lurbinectedin has been studied in multiple advanced cancers, but the amount of “life extension” depends on:
- the specific cancer type (for example, small cell lung cancer vs. other solid tumors),
- prior treatments,
- whether patients received lurbinectedin as monotherapy or in combination,
- and the trial’s endpoint (median overall survival vs. progression-free survival).
The necessary trial survival figures are not included in the provided material.
Did it improve overall survival or only delay progression?
“Extends life” usually refers to overall survival (OS), not progression-free survival (PFS). Some cancer drugs show improvements in PFS without a clear OS gain. The information available here does not state whether lurbinectedin improved OS in late-stage settings or how large that effect was.
What do people usually search for next (and what’s missing here)?
Common follow-up questions are:
- “What was the median overall survival with lurbinectedin?”
- “How does it compare to placebo/standard care?”
- “What was the confidence interval for OS?”
- “In which exact trial and cancer type was the benefit measured?”
Those details are not present in the provided information.
If you share the trial/cancer type, I can calculate the life-extension range
If you tell me the cancer type and setting (for example, “late-stage small cell lung cancer after platinum chemotherapy”) or the exact study name, I can help translate the reported OS and comparison arms into a clear “how much it extends life” answer.